Date: Monday, May 1, 2017
Session Time: 2:30pm-4:00pm
Presentation Time: 3:42pm-3:54pm
Introduction: Chagas disease is one of the most expanded endemic in Latin America with 8 people from every 10.000.000 being infected. In Argentina its estimated that about 4% of general population is infected. One of the non vector-born transmission routes descripted is through organ transplant. According to data published by our country on 2007 the prevalence of donors with chagasic infections(ChD) was of 4.82%, whilst those who were candidates for transplant represented a 2%.
Objetive: To describe prevalence and outcome of chagas infection in renal transplant and recipients seronegative from seropositive donors.
Materials and Methods :Retrospective study of renal transplant patients in our service .Both receivers with chagasic infection (ChR) and patients transplanted with ChD between January 1996 and November 2016 were considered. Chagas infection was defined by 2 or more positive serologies anti-Trypanosoma that included ELISA,HAI and CLIA. In the positive cases parasitaemia was performed during the pretransplant evaluation and at the moment of the transplant an informed agreement of the receivers who were goning to receive a ChD was requested. Monitoring was conducted with weekly strout for two months, every fifteen days for six months, monthly until one or two years and, and always clinical mafestations.
Results : 764 renal transplants were performed during the aforementioned period, of which 12 (1,57%) received a graft of ChD, 44 ChR (5,7%) and one patient with ChD and ChR. We have only observed one case of chagasic primoinfection (7,69%) detected by Strout test, asymptomatic patient. There were three recoveries (6,67%) a cardiac, a lymph nodes and an asymptomatic one.
Discussion: This is the largest series of chagasic patients and receivers reported to this day in literature. In our experience, renal transplants with chagasic donors and/or receivers have a low rate of primoinfection and recovery, with a possibility of therapy without this having any repercussion on the patient's survival. Every patient was treated with benznidazol 5 mg/kg/day for 30-60 days with a good response and tolerance. Conclusion:
[middot] Seroprevalence in our community is higher than the general population in our country (5.7% de RCh).
[middot] Even though serious complications such as encephalitis and panniculitis are commonly described, these did not occur within our sample group.
[middot] Renal transplant in chagasic patients or those recipients of chagasic donors seems to be safe if strict monitoring postrasplant .
CITATION INFORMATION: Taylor M, Martinoia A, Di PIetrantonio S, Torres M, Petrone H. Chagas Disease and Outcome in Kidney Transplant. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Taylor M, Martinoia A, PIetrantonio SDi, Torres M, Petrone H. Chagas Disease and Outcome in Kidney Transplant. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/chagas-disease-and-outcome-in-kidney-transplant/. Accessed October 31, 2020.
« Back to 2017 American Transplant Congress